External Control Arm 
Images and Algorithms
Rare Tumor Registries 
Immune-Related Adverse Events 
The Merkel Cell Carcinoma (MCC) Patient Registry initiative organized by Project Data Sphere is off to a fast start in 2022 with four manuscripts accepted for publication.
Home
Convener, collaborator, catalyst in the fight against cancer.
At Project Data Sphere®, we believe in breaking down barriers to cancer clinical trial data sharing — barriers that historically have kept valuable trial data from ultimately benefitting the patients who so selflessly participate in them. By aggregating trial data from biopharmaceutical companies, academic medical centers, and government organizations and making it freely available on our open-access platform, we have established ourselves as a premier resource for the global oncology research community. Our deep relationships with renowned oncology experts allow us to convene research collaborations that leverage the power of pooled clinical trial data and which ultimately position PDS to be a catalyst for the discovery of urgently needed new treatments while helping to make cancer trials faster, more effective, and less expensive.
Data Providers
Sponsored Research
Conducting late-stage cancer trials without the need for a comparator arm could reduce patient enrollment time, cut costs, and preserve patient availability for other trials. Project Data Sphere's External Control Arm program is focused on making this a reality for cancer trials.
Manually quantifying the size of solid tumors is both slow and subject to inter-reader variability. The Images and Algorithms program was created to accelerate these measurements and reduce inter-reader variability by developing a machine-learning algorithm to augment independent radiologist readings.
Project Data Sphere’s MCC Tumor Registry is a prototype for a reliable source of publicly accessible information on rare diseases. Aggregating prospective patient-level data from multiple clinical sites, the registry offers an important source of information for natural history studies and, potentially, proof-of-concept for using real-world evidence in the drug-approval process.
Project Data Sphere is driving solutions that remove barriers to data sharing in order to improve patient outcomes and expand cancer treatment options. The Immune-Related Adverse Events research program supports initiatives dedicated to improving the safety and efficacy of powerful immunotherapy treatments and decreasing the impact of associated adverse events.
Latest News
Project Data Sphere’s Images & Algorithms (I&A) Program presented preliminary results from its autoRECIST project at the FDA Research Grand Rounds on Feb. 25. Nearly 200 attendees participated in this webinar which generated a great discussion.
